Latest news with #BIIB
Business Insider
2 days ago
- Business
- Business Insider
Biogen (BIIB) Receives a Buy from TD Cowen
TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $175.00. The company's shares closed today at $133.06. Confident Investing Starts Here: Nadeau covers the Healthcare sector, focusing on stocks such as Biogen, BioMarin Pharmaceutical, and Kura Oncology. According to TipRanks, Nadeau has an average return of 2.6% and a 42.41% success rate on recommended stocks. In addition to TD Cowen, Biogen also received a Buy from William Blair's Myles Minter in a report issued today. However, on the same day, Stifel Nicolaus reiterated a Hold rating on Biogen (NASDAQ: BIIB). BIIB market cap is currently $19.85B and has a P/E ratio of 13.38. Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BIIB in relation to earlier this year. Last month, Caroline Dorsa, a Director at BIIB bought 1,235.00 shares for a total of $151,559.20.
Yahoo
28-05-2025
- Business
- Yahoo
Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal
Biogen Inc. (NASDAQ:BIIB)'s recent partnership with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases has fueled a 6% rise in its share price over the past month, reflecting renewed investor optimism. This move comes amid a broader rally in the tech sector driven by favorable policy shifts and positive market sentiment, as major indices have also trended upward. A scientist studying a petri dish with magnifying glass in a laboratory setting. The collaboration underscores Biogen Inc. (NASDAQ:BIIB)'s strategic pivot toward innovative treatments, expanding its pipeline beyond established Alzheimer's therapies like LEQEMBI. Analysts suggest this could strengthen BIIB's long-term growth prospects and help offset challenges such as declining multiple sclerosis revenues and mounting competition from generics and biosimilars. Despite the recent uptick, Biogen Inc. (NASDAQ:BIIB)'s three-year total shareholder return remains down 37.09%, significantly underperforming the broader US biotech industry, which gained 12.9% over the past year. The company's current share price still trades at a 36.67% discount to the analyst consensus target of $171.95, highlighting persistent investor caution regarding future earnings and revenue growth. While the RNAi collaboration may gradually shift market perceptions, BIIB faces ongoing pressure to deliver on its innovation-driven strategy and regain industry momentum. While we acknowledge the potential of BIIB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIIB and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-05-2025
- Business
- Yahoo
Biogen (NasdaqGS:BIIB) Selects Multiple Co-Lead Underwriters for US$1 Billion Fixed-Income Offering
Biogen appointed multiple co-lead underwriters for two fixed-income offerings totaling over $1 billion, showcasing its efforts to bolster financial offerings. This move, coupled with Biogen's recent earnings announcement, which reported a decline in net income and sales but an increase in revenue, did not align with the generally stable market performance over the same period. While these developments reflect Biogen's current financial strategies and performance, they could have added pressure to its 3% price decline last week amidst a mixed equities market and investor focus on broader economic factors such as the Fed's rate decisions. You should learn about the 2 possible red flags we've spotted with Biogen. NasdaqGS:BIIB Revenue & Expenses Breakdown as at May 2025 Uncover 16 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The appointment of underwriters for Biogen's fixed-income offerings could potentially strengthen its liquidity position amidst recent financial challenges. As the company navigates a decline in net income and sales, this move might ease pressure on its finances and assist in financing new product initiatives, particularly the promising therapies in Alzheimer's and ALS. However, these financing strategies have not staved off a recent share price decline of 3%, suggesting that investors remain cautious amid mixed market signals and broader economic variables like the Federal Reserve's rate decisions. Over the past three years, Biogen's total shareholder return, including share price and dividends, was 40.09% lower, highlighting a significant underperformance. Meanwhile, in the past year, Biogen's performance lagged behind the broader US market, which saw a return of 7.2%, and also fell short of the US Biotechs industry that recorded a return of 14.1%. This gap underscores the ongoing challenges Biogen faces in maintaining investor confidence and aligning its financial strategies with market trends. The recent news about its fixed-income offerings could positively impact the company's revenue and earnings forecasts, particularly as Biogen continues to focus on innovative therapies. Although analysts forecast a 0.9% annual decline in revenue over the next three years, advancements like LEQEMBI might alter this outlook if adopted widely. Regarding the price target, Biogen's current share price of US$120.17 is notably below the consensus analyst target of US$173.52, indicating considerable room for potential value adjustment as the company addresses its operational and strategic objectives. The valuation report we've compiled suggests that Biogen's current price could be quite moderate.
Yahoo
06-05-2025
- Business
- Yahoo
2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo. This is precisely where StockStory comes in - we do the heavy lifting to identify companies with solid fundamentals so you can invest with confidence. That said, here are two mid-cap stocks with massive growth potential and one that could be down big. Market Cap: $17.85 billion Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ:BIIB) develops and markets therapies for neurological conditions, including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and rare diseases. Why Do We Steer Clear of BIIB? Customers postponed purchases of its products and services this cycle as its revenue declined by 7.4% annually over the last five years Projected sales decline of 7.3% over the next 12 months indicates demand will continue deteriorating Earnings per share decreased by more than its revenue over the last five years, showing each sale was less profitable Biogen is trading at $122.47 per share, or 7.6x forward P/E. Check out our free in-depth research report to learn more about why BIIB doesn't pass our bar. Market Cap: $15.32 billion Formed through the merger of 12 companies, Comfort Systems (NYSE:FIX) provides mechanical and electrical contracting services. Why Do We Love FIX? Average backlog growth of 30.5% over the past two years shows it has a steady sales pipeline that will drive future orders Earnings growth has massively outpaced its peers over the last two years as its EPS has compounded at 68.2% annually Returns on capital are growing as management capitalizes on its market opportunities Comfort Systems's stock price of $444.72 implies a valuation ratio of 23.3x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it's free. Market Cap: $29.75 billion Serving nearly 1 in 15 Americans through its government healthcare programs, Centene (NYSE:CNC) is a healthcare company that manages government-sponsored health insurance programs like Medicaid and Medicare for low-income and complex-needs populations. Why Could CNC Be a Winner? 15.5% annual revenue growth over the last five years surpassed the sector average as its offerings resonated with customers Dominant market position is represented by its $169.3 billion in revenue, which gives it negotiating power over membership pricing and reimbursement rates Earnings growth has trumped its peers over the last five years as its EPS has compounded at 14.8% annually At $59.78 per share, Centene trades at 7.8x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like United Rentals (+322% five-year return). Find your next big winner with StockStory today for free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-04-2025
- Business
- Yahoo
1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. Luckily for you, StockStory helps you navigate which companies are truly worth holding. Keeping that in mind, here is one low-volatility stock that could succeed under all market conditions and two stuck in limbo. Rolling One-Year Beta: 0.73 Based on a nautical reference to the first work shift aboard a ship, First Watch (NASDAQ:FWRG) is a chain of breakfast and brunch restaurants whose menu is heavily-focused on eggs and griddle items such as pancakes. Why Are We Wary of FWRG? Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of -0.5% for the last two years ROIC of 2.1% reflects management's challenges in identifying attractive investment opportunities Depletion of cash reserves could lead to a fundraising event that triggers shareholder dilution At $19.54 per share, First Watch trades at 48.6x forward price-to-earnings. Check out our free in-depth research report to learn more about why FWRG doesn't pass our bar. Rolling One-Year Beta: 0.57 Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ:BIIB) develops and markets therapies for neurological conditions, including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and rare diseases. Why Should You Sell BIIB? Sales tumbled by 7.6% annually over the last five years, showing market trends are working against its favor during this cycle Performance over the past five years shows each sale was less profitable as its earnings per share dropped by 13.3% annually, worse than its revenue Waning returns on capital imply its previous profit engines are losing steam Biogen's stock price of $118.15 implies a valuation ratio of 7.3x forward price-to-earnings. If you're considering BIIB for your portfolio, see our FREE research report to learn more. Rolling One-Year Beta: -0.04 Transforming how doctors care for seniors by shifting financial incentives from volume to outcomes, agilon health (NYSE:AGL) provides a platform that helps primary care physicians transition to value-based care models for Medicare patients through long-term partnerships and global capitation arrangements. Why Do We Like AGL? Annual revenue growth of 51.7% over the past two years was outstanding, reflecting market share gains this cycle Customer growth averaged 41.2% over the past two years, showing its ability to "land" new contracts and potentially "expand" them later - a powerful one-two punch for sales Cash-burning tendencies have improved over the last five years, showing it could become financially independent one day agilon health is trading at $4.01 per share, or 0.3x forward price-to-sales. Is now the right time to buy? Find out in our full research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Axon (+711% five-year return). Find your next big winner with StockStory today for free.
